Skip to content
Reviewed against editorial standards · Updated 2026-02-27

Semaglutide: Dosage & Administration

Part of the Semaglutide Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

Advertiser link — we may earn a commission at no extra cost to you.

Dosage Protocols

BrandIndicationStartingTargetRoute
OzempicType 2 Diabetes0.25 mg/week × 4 wks0.5–1 mg/weekSC injection
WegovyWeight Management0.25 mg/week × 4 wks2.4 mg/weekSC injection
RybelsusType 2 Diabetes3 mg/day × 30 days7–14 mg/dayOral tablet

Dose escalation for Wegovy follows a 16-week schedule: 0.25 mg (weeks 1–4), 0.5 mg (weeks 5–8), 1.0 mg (weeks 9–12), 1.7 mg (weeks 13–16), then 2.4 mg maintenance. This gradual increase minimizes GI side effects.

Administration

Semaglutide injections (Ozempic/Wegovy) come in pre-filled pens — no reconstitution required. Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites. Administer on the same day each week at any time, with or without meals.

Rybelsus oral tablets must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before food, drink, or other medications. This is critical for absorption.

Timing & Duration

Semaglutide is prescribed for long-term use — there is no cycling. Weight regain typically occurs after discontinuation (STEP 1 extension showed ~2/3 weight regain within 1 year). For type 2 diabetes, treatment is ongoing as long as benefit is maintained.

If a dose is missed, take it within 5 days of the scheduled day. If more than 5 days have passed, skip and resume the next scheduled dose.

Storage

  • Unopened pens: Refrigerate at 2–8°C. Do not freeze.
  • In-use pens: Store at room temperature (up to 30°C) or refrigerated for up to 56 days
  • Rybelsus tablets: Store at room temperature in original blister packaging
  • Protect from excessive heat and light

FAQ

Frequently Asked Questions

References

  1. [1] Wilding JPH, et al.. Once-weekly semaglutide in adults with overweight or obesity. NEJM, 2021.
  2. [2] Knop FK, et al.. Oral semaglutide 50 mg taken once daily in adults with overweight or obesity (OASIS 1). Lancet, 2023.

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

No spam · Unsubscribe anytime

Related Reading

AD
Austin Danner

Founder & Editor in Chief

Founder of Peptides Insider. Independent researcher focused on translating peer-reviewed peptide research into practical, evidence-based guides.

Reviewed against Peptides Insider editorial standards · Last reviewed 2026-02-27.